TheraRadar
← Back
Data updated: Jun 28, 2026

ARDELYX INC

Pharma
GastroenterologyMetabolic Execution: Good

ARDELYX INC is a pharmaceutical company focused on Gastroenterology, Metabolic. Key products include IBSRELA.

2019
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

FDA Novel Drug Designations

(2019)
1 Novel 1 First-in-Class
See 1 novel approval →
2019 IBSRELA (TENAPANOR HYDROCHLORIDE) First-in-Class

ARDELYX INC at a Glance

  • Fast trial execution (9 months median completion)

ARDELYX INC's Key Drugs

ARDELYX INC's core commercial portfolio centers on XPHOZAH, IBSRELA, spanning Gastroenterology and Metabolic — its most strategically important drugs approved in the last 15 years.

XPHOZAH
Gastrointestinal

Irritable Bowel Syndrome with Constipation

NHE3 Approved 2023
IBSRELA
Gastrointestinal

Irritable Bowel Syndrome with Constipation

NHE3 Approved 2019

ARDELYX INC's Recent FDA Approvals

New NDA/BLA approvals for ARDELYX INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ARDELYX INC's Therapeutic Areas

ARDELYX INC's approved drugs and pipeline span 2 therapeutic areas, led by Gastroenterology and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Gastroenterology 83%
0 drugs Phase 3: 2 Phase 2: 1
Metabolic 17%
0 drugs Phase 2: 1

ARDELYX INC's Top Competitors

ARDELYX INC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Takeda, and ASTELLAS. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Gastroenterology, Metabolic
Takeda big-pharma
Metabolic, Gastroenterology
ASTELLAS specialty
Metabolic, Gastroenterology
Amgen biotech
Metabolic, Gastroenterology
EMD SERONO biotech
Metabolic, Gastroenterology

ARDELYX INC Pipeline Snapshot

ARDELYX INC has 4 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 2 Phase 2 and 0 Phase 1.

2
Phase 3
2
Phase 2
0
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q1 2027
Tenapanor 5 mg BID
Chronic Idiopathic Constipation (CIC)
Estimated · fresh NCT07382167

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • XPHOZAH leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Gastroenterology pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 5/8 completed
  • • Speed: 9 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges